Cargando…
External validation suggests Integrin beta 3 as prognostic biomarker in serous ovarian adenocarcinomas
BACKGROUND: The majority of women with ovarian cancer are diagnosed in late stages, and the mortality rate is high. The use of biomarkers as prognostic factors may improve the treatment and clinical outcome of these patients. We performed an external validation of the potential biomarkers CLU, ITGB3...
| Autores principales: | , , , , , |
|---|---|
| Formato: | Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2009
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2754489/ https://www.ncbi.nlm.nih.gov/pubmed/19775429 http://dx.doi.org/10.1186/1471-2407-9-336 |